From the Guidelines
Elevated ferritin and alkaline phosphatase levels in a patient should be managed with a systematic diagnostic approach to identify the underlying cause, with hemochromatosis being a key consideration, and treatment may involve regular phlebotomy to reduce iron stores, as recommended by the American Association for the Study of Liver Diseases 1. The diagnostic approach should include a comprehensive medical history, physical examination, and additional laboratory tests, such as complete liver function tests, complete blood count, iron studies (serum iron, total iron binding capacity, transferrin saturation), and inflammatory markers. Imaging studies, like abdominal ultrasound or CT scan, may be necessary to evaluate the liver and biliary system. Some key points to consider in the management of elevated ferritin and alkaline phosphatase include:
- Common causes for this combination include hemochromatosis, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, and certain medications.
- For hemochromatosis, treatment involves regular phlebotomy (removal of 500 mL of blood weekly or biweekly) until ferritin levels normalize, followed by maintenance phlebotomy, as outlined in the 2011 practice guideline by the American Association for the Study of Liver Diseases 1.
- The decision to treat hemochromatosis with phlebotomy is straightforward for patients with evidence of liver disease or other end-organ manifestations, but may also be considered for asymptomatic patients with elevated ferritin levels, given the ease, safety, and potential benefits of treatment, including blood donation 1.
- Cardiac involvement in iron overload can be diagnosed with cardiac MRI, and early identification is crucial, as cardiomyopathy develops late in the disease process, often when treatment is no longer possible, as noted in the American Heart Association scientific statement 2.
From the Research
Diagnosis of Elevated Ferritin and Alkaline Phosphatase
- Elevated ferritin levels can indicate iron overload, which can be caused by various factors such as regular blood transfusions, hereditary hemochromatosis, or transfusional siderosis 3, 4.
- Alkaline phosphatase (alk phos) elevations can suggest disease of the liver or bone, but defective enzyme elimination can also play a role in the pathogenesis of serum alk phos elevations 5.
- A stepwise evaluation should be initiated to determine the cause of mildly elevated liver transaminase levels, including a fasting lipid profile, measurement of glucose, serum iron, and ferritin, total iron-binding capacity, and hepatitis B surface antigen and hepatitis C virus antibody testing 6.
Management of Elevated Ferritin and Alkaline Phosphatase
- Iron chelation therapy, such as deferoxamine, deferiprone, or deferasirox, can be used to treat iron overload 4, 7.
- Phlebotomy is the initial treatment of choice in hemochromatosis, while chelation is a mainstay in the treatment of transfusional siderosis 4.
- Serum ferritin thresholds can be used to predict clinically relevant liver iron concentrations and guide iron chelation therapy when MRI is unavailable 7.
- The optimal cutoff value for iron overload using serum glycosylated ferritin level was found to be >587.55 ng/mL 3.
Further Evaluation and Testing
- Initial testing should include a fasting lipid profile, measurement of glucose, serum iron, and ferritin, total iron-binding capacity, and hepatitis B surface antigen and hepatitis C virus antibody testing 6.
- Additional testing may include ultrasonography, measurement of α(1)-antitrypsin and ceruloplasmin, serum protein electrophoresis, and antinuclear antibody, smooth muscle antibody, and liver/kidney microsomal antibody type 1 testing 6.
- Referral for further evaluation and possible liver biopsy is recommended if transaminase levels remain elevated for six months or more 6.